Epithelium removal not necessary for collagen cross-linking

Article

Corneal collagen cross-linking with riboflavin, without removing the epithelium, is both safe and effective.

Corneal collagen cross-linking with riboflavin, without removing the epithelium, is both safe and effective, according to Roberto Pinelli, ILMO, Brescia, Italy.

Dr Pinelli examined two groups of five keratoconic patients. Group A was treated monocularly without removing the epithelium and Group B was treated after epithelial removal. Custom-made riboflavin eye-drops were applied to the cornea and activated by UV-A.

Dr Pinelli noted no significant differences between the two groups postoperatively. The 30 eyes in Group A, at 18 months follow-up, showed a mean K reduction of 0.83 D, higher K reduction in the 3 mm central zone, a mean uncorrected visual acuity (UCVA) improvement of 1.3 lines, a mean best spectacle corrected visual acuity (BSCVA) and an increase in central pachymetry. Furthermore, keratoconus progression was halted in all eyes.

These results demonstrate that it is not necessary to remove the epithelium in order for riboflavin to effectively penetrate the cornea.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.